Any current/future new fundraising through debt or equity?

There is no specific mention of any current or future fundraising through debt or equity in the provided transcript. The company has been focusing on capex projects funded internally, with an annual capex range of INR 80 to 100 crores. The management discussed ongoing capex for pharma intermediates (INR 60 crores) and OAP (INR 15 crores) but did not indicate raising funds through equity or debt. They mentioned managing working capital and improving cash flows post-Sarigam incident, with some reduction in short-term borrowing. No explicit plans for raising debt or equity were stated during the

Any current/future capex/capital investment/strategic investment?

Ongoing capex includes INR 15 crores for OAP (Ortho Anisic Phenol) and INR 60 crores for pharma intermediates, totaling around INR 75 crores. Pharma intermediates capex is completed with trial runs done and awaiting government approvals (expected by end Q3 FY '23). OAP capex is still ongoing with trial runs and some additional capex expected. After commissioning these projects, further capex plans are unclear; typically, the company does INR 80-100 crores of annual capex. The company is also analyzing new product opportunities, potentially involving a modest capex of around INR 40-45 crores if

Future growth expectations in sales/revenue/volumes?

The company expects revenue growth of 5% to 10% for the current financial year (FY23), targeting INR 1,000 to 1,100 crores on a standalone basis. For FY24 and beyond, a growth of around 30% is anticipated with full ramp-up of PAP (para Aminophenol), OAP (other agrochemicals project), and pharma intermediates. Pharma intermediates plant expected to reach around 45-50% utilization in initial quarters of FY24 and full utilization by end of FY24, targeting about INR 50 crores revenue at full capacity. Continuous process for PAP expected to increase production capacity from 500 to 1,000 metri

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a turnover of around INR 60 crores from the pharma intermediates product, with an asset turnover of approximately 1x, potentially a little more. Margins for pharma intermediates are expected to be aligned with company-level margins; specific product margins are not disclosed. Revenues were impacted by the Sarigam incident, causing a top-line loss of around 15-20% quarterly; full production recovery is expected by March, with growth of 5-10% by year-end on a standalone basis. For FY '23, an average EBITDA margin of around 17% is anticipated, improving from earlier quarters d

Current/ Expected Orderbook/ Pending Orders?

The Sarigam plant had an incident impacting production and order fulfillment, causing a phased restart and lag in order execution. The management mentioned a lag in fulfilling certain orders due to the Sarigam plant being non-operational and phased ramp-up post-incident. Global demand issues, especially in Europe due to geopolitical and energy crisis, have also affected export order volumes. The company expects a recovery in production and order execution once the Sarigam plant stabilizes and global demand improves. New product development and capex for pharma intermediates and OAP are underwa

IN US

Sale is live|00:00:00left today

Valiant Organics LtdQ3 FY22Chemicals & Petrochemicals

Valiant Organics Ltd Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹280P/E: 27.6Market Cap: ₹831 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects revenue growth of 5% to 10% for the current financial year (FY23), targeting INR 1,000 to 1,100 crores on a standalone basis.
→For FY24 and beyond, a growth of around 30% is anticipated with full ramp-up of PAP (para Aminophenol), OAP (other agrochemicals project), and pharma intermediates.
→Pharma intermediates plant expected to reach around 45-50% utilization in initial quarters of FY24 and full utilization by end of FY24, targeting about INR 50 crores revenue at full capacity.
→Continuous process for PAP expected to increase production capacity from 500 to 1,000 metric tons per month once technical challenges are resolved, likely in upcoming financial years.
→Volume recovery at Sarigam plant to full original levels (~4,000-4,500 tons per quarter) by Q4 FY23.
→Overall growth driven by stabilizing raw material prices, operational improvements, and new product launches.

Margin guidance

Category 3

→The company expects a turnover of around INR 60 crores from the pharma intermediates product, with an asset turnover of approximately 1x, potentially a little more.
→Margins for pharma intermediates are expected to be aligned with company-level margins; specific product margins are not disclosed.
→Revenues were impacted by the Sarigam incident, causing a top-line loss of around 15-20% quarterly; full production recovery is expected by March, with growth of 5-10% by year-end on a standalone basis.
→For FY '23, an average EBITDA margin of around 17% is anticipated, improving from earlier quarters due to stabilized raw material costs; margins of 17-18% projected full-year.
→Post stabilization, the company targets 30% growth in the following year, driven by full utilization of PAP, along with OAP and pharma intermediates ramp-up.
→Annual capex is targeted around INR 80-100 crores to support growth.
→Long-term ROC improvements are expected but uncertain if pre-challenge historic levels (40%-60%) will be reached soon.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no specific mention of any current or future fundraising through debt or equity in the provided transcript.
→The company has been focusing on capex projects funded internally, with an annual capex range of INR 80 to 100 crores.
→The management discussed ongoing capex for pharma intermediates (INR 60 crores) and OAP (INR 15 crores) but did not indicate raising funds through equity or debt.
→They mentioned managing working capital and improving cash flows post-Sarigam incident, with some reduction in short-term borrowing.
→No explicit plans for raising debt or equity were stated during the Q&A or management comments.

Order book

→The Sarigam plant had an incident impacting production and order fulfillment, causing a phased restart and lag in order execution.
→The management mentioned a lag in fulfilling certain orders due to the Sarigam plant being non-operational and phased ramp-up post-incident.
→Global demand issues, especially in Europe due to geopolitical and energy crisis, have also affected export order volumes.
→The company expects a recovery in production and order execution once the Sarigam plant stabilizes and global demand improves.
→New product development and capex for pharma intermediates and OAP are underway, with expectations to increase revenues and order inflow upon commissioning.
→No specific quantitative orderbook or pending order values were disclosed in the transcript.

Capex plans

Yes

→Ongoing capex includes INR 15 crores for OAP (Ortho Anisic Phenol) and INR 60 crores for pharma intermediates, totaling around INR 75 crores.
→Pharma intermediates capex is completed with trial runs done and awaiting government approvals (expected by end Q3 FY '23).
→OAP capex is still ongoing with trial runs and some additional capex expected.
→After commissioning these projects, further capex plans are unclear; typically, the company does INR 80-100 crores of annual capex.
→The company is also analyzing new product opportunities, potentially involving a modest capex of around INR 40-45 crores if successful.
→Focus remains on stabilizing current projects before launching new large investments.
→The pharma intermediates plant will be captive to Aarti Pharmalabs.
→Continuous development and trials ongoing to shift PAP production from batch to continuous process for efficiency gains.

How does Valiant Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Valiant Organics Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Valiant Organics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio